Literature DB >> 2882404

Classical and late-onset forms of congenital adrenal hyperplasia caused by 21-OH deficiency reveal different alterations in the C4/21-OH gene region.

B O Boehm, C Rosak, T L Boehm, P Kuehnl, P C White, K Schöffling.   

Abstract

Congenital adrenal hyperplasia (CAH) is due to defective adrenal cortisol biosynthesis. In most cases, deficiency of a P 450-C21 specific steroid hydroxylase impairing cortisol synthesis has been found. The disease is HLA-linked, and on clinical grounds it can be divided into two major forms, the classical and the non-classical type. Here, evidence is presented that the classical and the non-classical forms of CAH caused by 21-OH deficiency are due to different genetic alterations in the C4/21-OH gene region. In most cases of classical CAH associated with the HLA-Bw47 antigen, a specific and selective loss of the 21-OH B gene was observed with some interesting exceptions. Alterations in the 21-OH gene region in the non-classical forms of CAH, patients either HLA-B14; DR1 homo- or heterozygous, are different. Our data indicate the possibility of gene conversion events in this genomic region in non-classical CAH.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2882404

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  3 in total

1.  21-hydroxylase deficiency families with HLA identical affected and unaffected sibs.

Authors:  P J Sinnott; P A Dyer; D A Price; R Harris; T Strachan
Journal:  J Med Genet       Date:  1989-01       Impact factor: 6.318

2.  Altered CYP21 genes in HLA-haplotypes associated with congenital adrenal hyperplasia (CAH): a family study.

Authors:  B J Manfras; M Swinyard; W A Rudert; E J Ball; P A Lee; P Kühnl; M Trucco; B O Böhm
Journal:  Hum Genet       Date:  1993-08       Impact factor: 4.132

3.  Pulsed field gel electrophoresis identifies a high degree of variability in the number of tandem 21-hydroxylase and complement C4 gene repeats in 21-hydroxylase deficiency haplotypes.

Authors:  S Collier; P J Sinnott; P A Dyer; D A Price; R Harris; T Strachan
Journal:  EMBO J       Date:  1989-05       Impact factor: 11.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.